Focus: Neuronetics is a publicly traded medical device company specializing in Transcranial Magnetic Stimulation (TMS) therapy for psychiatric and neurological disorders, with 5,000+ employees and revenue of $71M.
Profile data last refreshed 10h ago · AI intelligence enriched 1mo ago
Growing — net +9 jobs in 30d
44 jobs added vs 35 removed. Steady team buildout.
Good fit for supply chain, operations, and clinical specialists seeking stability; risky for R&D-focused roles given constrained innovation spending and persistent losses.
Help build intelligence for Neuronetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neuronetics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: Harmony Biosciences Holdings, Inc. (HRMY) (CIK 0001802665) — EX-99.1
EX-99.1
Neuronetics Inc Lobbying Profile, 2023 - OpenSecrets
Neuronetics Inc Lobbying Profile, 2023 OpenSecrets
Nir Naor is Named Chief Financial Officer at Neuronetics - Medical Product Outsourcing
Nir Naor is Named Chief Financial Officer at Neuronetics Medical Product Outsourcing
Neuronetics (NasdaqGM:STIM) Stock Forecast & Analyst Predictions - Simply Wall Street
Neuronetics (NasdaqGM:STIM) Stock Forecast & Analyst Predictions Simply Wall Street
Neuronetics a new buy at B Riley on interventional psychiatry platform - Seeking Alpha
Neuronetics a new buy at B Riley on interventional psychiatry platform Seeking Alpha
Neuronetics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Neuronetics, Inc. Q2 2026 Earnings Call Summary Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo